Targeting procaspase-3 with WF-208, a novel PAC-1 derivative, causes selective cancer cell apoptosis

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Caspase-3 is a key enzyme in apoptosis, frequently overexpressed in cancers.
• PAC-1, a procaspase-3 activator, demonstrates anti-cancer effects but has limitations.
• Developing more potent and selective procaspase-3 activators is crucial for cancer therapy.

Purpose of the Study:

• To design and synthesize novel compounds targeting procaspase-3 activation.
• To evaluate the efficacy and selectivity of new compounds against cancer cells.
• To compare the anti-tumor activity of lead compounds with existing treatments like PAC-1.

Main Methods:

• Synthesis and in vitro evaluation of novel procaspase-3 activators.
• Cytotoxicity assays on cancer cell lines (HL-60) and normal cells.
• Western blot analysis to assess procaspase-3 activation and Inhibitors of Apoptosis Proteins (IAPs) degradation.
• In vivo anti-tumor efficacy studies in murine xenograft models.

Main Results:

• WF-208 demonstrated high cytotoxicity against procaspase-3 overexpressing cancer cells.
• WF-208 exhibited superior anti-cancer activity and lower toxicity to normal cells compared to PAC-1.
• WF-208 induced caspase-3-dependent cell death by activating procaspase-3 and degrading IAPs, potentially via zinc chelation.
• WF-208 showed enhanced anti-tumor efficacy in a murine xenograft model.

Conclusions:

• WF-208 is identified as a potent procaspase-3 activating compound.
• WF-208 displays improved activity and cell selectivity over PAC-1.
• WF-208 represents a promising therapeutic candidate for cancer treatment.